ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

islatravir

Also written as “DOR/ISL”, “Islatravir” and “ISL”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Infections, led by 2 companies.

Drug pageIslatravir: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 8, 202028 company-led studies, 8 open or runningNext primary completion: Aug 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only277 open or runningphase 3since Jan 8, 2020Aug 13, 2014Aug 10, 2027phase 2 · NCT06891066
Gilead Sciences11 open or runningphase 2since Sep 13, 2021Sep 13, 2021none ahead
  • Named in Merck’s own pipeline as islatravir + lenacapavir (MK-8591D), phase 3, as of Nov 2, 2026 (source).
  • Named in Merck’s own pipeline as islatravir + ulonivirine (MK-8591B), phase 2, as of Nov 2, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named islatravirINNProposed as its International Nonproprietary Name in WHO's List 120
  2. Sep 13, 2021First study: phase 2 study in HIV-1 InfectionFirst studyNCT05052996 · 142 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

The one study Gilead Sciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05052996HIV-1 Infection · United States2Active, not recruitingDec 19, 2023142

How it is read

Names in the registry

  • “DOR/ISL”, 11 entries
  • “Islatravir”, 11 entries
  • “ISL”, 5 entries
  • “Islatravir (ISL)”, 1 entry
  • “Doravirine/Islatravir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.